Chardan Capital:上调CervoMed评级

证券之星
13 Mar

Chardan Capital:上调CervoMed(CRVO.US)评级,由中性调整至买入评级,目标价14.00美元。CervoMed(CRVO.US)公司简介:CervoMed Inc是一家临床阶段的生物技术公司。该公司专注于开发与年龄相关的神经系统疾病的治疗方法。该公司的候选产品Neflamapimod有潜力治疗和改善突触功能障碍、提升DLB和某些其他神经系统疾病的潜在疾病过程的可逆性。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10